Fragment-based lead discovery (Q35852295)

10 August 2017

1 reference

title

Fragment-based lead discovery (English)

1 reference

10 August 2017

1 reference

David C Rees

1

1 reference

10 August 2017

Miles Congreve

series ordinal

2

1 reference

10 August 2017

Christopher W Murray

series ordinal

3

1 reference

10 August 2017

Robin Carr

series ordinal

4

1 reference

10 August 2017

1 August 2004

1 reference

Nature Reviews Drug Discovery

10 August 2017

1 reference

10 August 2017

3

1 reference

10 August 2017

8

1 reference

10 August 2017

660-672

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd1467

10 August 2017

0 references

cites work

Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening

1 reference

The SHAPES strategy: an NMR-based approach for lead generation in drug discovery.

31 March 2020

1 reference

Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors

31 March 2020

1 reference

PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors

31 March 2020

1 reference

On the attribution and additivity of binding energies

31 March 2020

1 reference

Discovering high-affinity ligands for proteins: SAR by NMR

31 March 2020

1 reference

31 March 2020

NMR in drug discovery

1 reference

The genesis of high-throughput structure-based drug discovery using protein crystallography

31 March 2020

1 reference

High-throughput crystallography for lead discovery in drug design.

31 March 2020

1 reference

Molecular complexity and its impact on the probability of finding leads for drug discovery

31 March 2020

1 reference

Is there a difference between leads and drugs? A historical perspective

31 March 2020

1 reference

A comparison of physiochemical property profiles of development and marketed oral drugs

31 March 2020

1 reference

Characteristic physical properties and structural fragments of marketed oral drugs.

31 March 2020

1 reference

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

31 March 2020

1 reference

Molecular properties that influence the oral bioavailability of drug candidates

31 March 2020

1 reference

A ‘Rule of Three’ for fragment-based lead discovery?

31 March 2020

1 reference

Site-directed ligand discovery

31 March 2020

1 reference

Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution

31 March 2020

1 reference

Combinatorial docking and combinatorial chemistry: design of potent non-peptide thrombin inhibitors

31 March 2020

1 reference

Structure-based screening as applied to human FABP4: a highly efficient alternative to HTS for hit generation

31 March 2020

1 reference

Novel inhibitors of Erm methyltransferases from NMR and parallel synthesis.

31 March 2020

1 reference

The consequences of translational and rotational entropy lost by small molecules on binding to proteins.

31 March 2020

1 reference

31 March 2020

1 reference

Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease.

31 March 2020

1 reference

Human beta-tryptase is a ring-like tetramer with active sites facing a central pore

31 March 2020

1 reference

Potent selective nonpeptidic inhibitors of human lung tryptase.

31 March 2020

1 reference

Dibasic inhibitors of human mast cell tryptase. Part 2: structure-activity relationships and requirements for potent activity

31 March 2020

1 reference

In situ assembly of enzyme inhibitors using extended tethering

31 March 2020

1 reference

Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy

31 March 2020

1 reference

Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor

31 March 2020

1 reference

SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets

31 March 2020

1 reference

Discovery of a potent small molecule IL-2 inhibitor through fragment assembly

31 March 2020

1 reference

Drug discovery by dynamic combinatorial libraries

31 March 2020

1 reference

Virtual combinatorial libraries: dynamic generation of molecular and supramolecular diversity by self-assembly

31 March 2020

1 reference

Ketones as building blocks for dynamic combinatorial libraries: highly active neuraminidase inhibitors generated via selection pressure of the biological target

31 March 2020

1 reference

Target-induced formation of neuraminidase inhibitors from in vitro virtual combinatorial libraries

31 March 2020

1 reference

Detection of ligands from a dynamic combinatorial library by X-ray crystallography.

31 March 2020

1 reference

Freeze-frame inhibitor captures acetylcholinesterase in a unique conformation

31 March 2020

1 reference

Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks

31 March 2020

1 reference

Identification of novel inhibitors of urokinase via NMR-based screening

31 March 2020

1 reference

Discovering novel ligands for macromolecules using X-ray crystallographic screening

31 March 2020

1 reference

SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2.

31 March 2020

1 reference

Requirements for Specific Binding of Low Affinity Inhibitor Fragments to the SH2 Domain ofpp60Src Are Identical to Those for High Affinity Binding of Full Length Inhibitors

31 March 2020

1 reference

Design of adenosine kinase inhibitors from the NMR-based screening of fragments

31 March 2020

1 reference

Ligand efficiency: a useful metric for lead selection

31 March 2020

1 reference

Fragment-Based Drug Discovery

31 March 2020

1 reference

Implications of protein flexibility for drug discovery

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD1467

1 reference

Dimensions Publication ID

10 August 2017

0 references

1 reference